OKYO Pharma (OKYO) Receivables - Net (2021 - 2026)
OKYO Pharma (OKYO) posted quarterly Receivables - Net of $375749.0 for Q1 2026, up 55.05% year-over-year from $242342.0 in Q1 2025, and up 55.05% quarter-over-quarter from $242342.0 in Q1 2025.
OKYO Pharma (OKYO) Receivables - Net (2021 - 2026) Analysis & Trends
OKYO Pharma (OKYO) has reported Receivables - Net for 6 consecutive years, with $375749.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Net rose 55.05% year-over-year to $375749.0; the TTM figure through Mar 2026 stood at $375749.0 (up 55.05% YoY), while the FY2026 annual figure was $375749.0, up 55.05% from the prior year.
- Receivables - Net advanced to $375749.0 in Q1 2026 per OKYO's latest filing, from $242342.0 in the prior quarter.
- Across five years, Receivables - Net topped out at $812956.0 in Q1 2022 and bottomed at $151938.0 in Q1 2024.
- Historically, Receivables - Net has averaged $435036.0 across 5 years, with a median of $375749.0 in 2026.
- Annual changes were most pronounced in 2022 — Receivables - Net jumped 1774.47% — and 2024, when it sank 74.34%.
- OKYO Pharma's Receivables - Net stood at $812956.0 in 2022, then dropped by 27.16% to $592195.0 in 2023, then slumped by 74.34% to $151938.0 in 2024, then jumped by 59.5% to $242342.0 in 2025, then surged by 55.05% to $375749.0 in 2026.
- Business Quant data shows OKYO's Receivables - Net at $375749.0 in Q1 2026, $242342.0 in Q1 2025, and $151938.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | OKYO Pharma | 1.47 Bn | 1.47 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 375,749.00 |
| Mar 31, 2026 | 375,749.00 |
| Mar 31, 2025 | 242,342.00 |
| Mar 31, 2025 | 242,342.00 |
| Mar 31, 2024 | 151,938.00 |
| Mar 31, 2024 | 151,938.00 |
| Mar 31, 2023 | 592,195.00 |
| Mar 31, 2023 | 592,195.00 |
| Mar 31, 2022 | 812,956.00 |
| Mar 31, 2022 | 812,956.00 |
| Mar 31, 2021 | 43,370.00 |
| Mar 31, 2021 | 43,370.00 |